Vytorin Fails To Show ENHANCEd Benefit Over Simvastatin In Plaque Reduction
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck/Schering-Plough felt pressure to release findings earlier than its scheduled presentation at March American College of Cardiology meeting, Schering-Plough tells “The Pink Sheet” DAILY.
You may also be interested in...
HCV Among Merck’s Gains With Schering, But Future Moves Still Murky
As Merck and Schering-Plough await a potential monkey wrench from Johnson & Johnson for their merger, observers are sorting through each company's partnerships for would-be redundancies
HCV Among Merck’s Gains With Schering, But Future Moves Still Murky
As Merck and Schering-Plough await a potential monkey wrench from Johnson & Johnson for their merger, observers are sorting through each company's partnerships for would-be redundancies
Vytorin Re-Endorsed By FDA Despite Lack Of Impact On Carotid Artery Thickness
Agency offers three possible explanations for why a reduction in LDL failed to translate into a drop in cIMT.